Evidence map›Paper›PMID 35721919›Full record

ArticleACS omega2022

Separation of Etiracetam Enantiomers Using Enantiospecific Cocrystallization with 2-Chloromandelic Acid.

Thitapond Nulek, Rachan Klaysri, Ruel Cedeno, Phattananawee Nalaoh, Sareeya Bureekaew, Vinich Promarak, Adrian E Flood

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thitapond NulekDepartment of Chemical and Biomolecular Engineering, School of Energy Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.
Rachan KlaysriDepartment of Chemical and Biomolecular Engineering, School of Energy Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.
Ruel CedenoDepartment of Chemical and Biomolecular Engineering, School of Energy Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.
Phattananawee NalaohDepartment of Materials Science and Engineering, School of Molecular Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.
Sareeya BureekaewDepartment of Chemical and Biomolecular Engineering, School of Energy Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.
Vinich PromarakDepartment of Materials Science and Engineering, School of Molecular Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.ORCID https://orcid.org/0000-0003-4805-9944
Adrian E FloodDepartment of Chemical and Biomolecular Engineering, School of Energy Science and Engineering, Vidyasirimedhi Institute of Science and Technology, 555 Moo 1, Payupnai, Wang Chan, 21210 Rayong, Thailand.ORCID https://orcid.org/0000-0003-1691-3085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chirality plays an important role in the pharmaceutical industry since the two enantiomers of a drug molecule usually display significantly different bioactivities, and hence, most products are produced as pure enantiomers. However, many drug precursors are synthesized as racemates, and hence, enantioseparation has become a significant process in the industry. Cocrystallization is one of the attractive crystallization approaches to obtain the desired enantiomer from racemic compounds. In this work, we propose a chiral resolution route for an antiepileptic drug,

Identifiers

PMID35721919
PMCPMC9202017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.